Sullivan Mark R, Rubin Eric J
Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA.
bioRxiv. 2024 Dec 16:2024.12.15.628588. doi: 10.1101/2024.12.15.628588.
Drugs must accumulate at their target site to be effective, and inadequate uptake of drugs is a substantial barrier to the design of potent therapies. This is particularly true in the development of antibiotics, as bacteria possess numerous barriers to prevent chemical uptake. Designing compounds that circumvent bacterial barriers and accumulate to high levels in cells could dramatically improve the success rate of antibiotic candidates. However, a comprehensive understanding of which chemical structures promote or prevent drug uptake is currently lacking. Here we use liquid chromatography-mass spectrometry to measure accumulation of 1528 approved drugs in , a highly drug-resistant, opportunistic pathogen. We find that simple chemical properties fail to effectively predict drug accumulation in mycobacteria. Instead, we use our data to train deep learning models that predict drug accumulation in with high accuracy, including for chemically diverse compounds not included in our original drug library. We find that differential drug uptake is a critical determinant of the efficacy of drugs currently in development and can identify compounds which accumulate well and have antibacterial activity in . These predictive algorithms can be an important complement to chemical synthesis and accumulation assays in the evaluation of drug candidates.
药物必须在其靶位点积累才能发挥作用,而药物摄取不足是设计有效疗法的重大障碍。在抗生素研发中尤其如此,因为细菌有许多屏障来阻止化学物质的摄取。设计能够绕过细菌屏障并在细胞中高水平积累的化合物,可能会显著提高抗生素候选药物的成功率。然而,目前尚缺乏对哪些化学结构促进或阻止药物摄取的全面理解。在这里,我们使用液相色谱 - 质谱法来测量1528种已批准药物在一种高度耐药的机会致病菌中的积累情况。我们发现简单的化学性质无法有效预测药物在分枝杆菌中的积累。相反,我们利用我们的数据训练深度学习模型,该模型能够高精度地预测药物在分枝杆菌中的积累,包括对我们原始药物库中未包含的化学结构多样的化合物。我们发现差异药物摄取是当前正在研发的药物疗效的关键决定因素,并且可以识别出在分枝杆菌中积累良好且具有抗菌活性的化合物。这些预测算法在评估候选药物时可以成为化学合成和积累测定的重要补充。